Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Denali Therapeutics Inc. | Director | Common Stock | 1,880,539 | $38.3 M | $20.39 | May 31, 2024 | Direct |
REGENERON PHARMACEUTICALS, INC. | Director | Common Stock | 2,434 | $2.32 M | $951.26 | Jan 3, 2023 | Direct |
Denali Therapeutics Inc. | Director | Common Stock | 79,173 | $1.61 M | $20.39 | May 31, 2024 | The Tessier-Lavigne/Hynes Irrevocable Trust 2 |
Denali Therapeutics Inc. | Director | Common Stock | 78,848 | $1.61 M | $20.39 | May 31, 2024 | The Tessier-Lavigne/Hynes Irrevocable Trust 1 |
Denali Therapeutics Inc. | Director | Common Stock | 78,848 | $1.61 M | $20.39 | May 31, 2024 | The Tessier-Lavigne/Hynes Irrevocable Trust 3 |
Denali Therapeutics Inc. | Director | Stock Option (right to buy) | 17,901 | May 31, 2024 | Direct | ||
REGENERON PHARMACEUTICALS, INC. | Director | Non-Qualified Stock Option (right to buy) | 1,929 | Jan 3, 2023 | Direct |